GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » EPS (Diluted)

Oxford Cannabinoid Technologies Holdings (FRA:0CB) EPS (Diluted) : €-0.01 (TTM As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings EPS (Diluted)?

Oxford Cannabinoid Technologies Holdings's Earnings per Share (Diluted) for the six months ended in Oct. 2023 was €-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was €-0.01.

Oxford Cannabinoid Technologies Holdings's EPS (Basic) for the six months ended in Oct. 2023 was €-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2023 was €-0.01.

Oxford Cannabinoid Technologies Holdings's EPS without NRI for the six months ended in Oct. 2023 was €-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2023 was €-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was -26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Oxford Cannabinoid Technologies Holdings's highest 3-Year average EPS without NRI Growth Rate was -26.00% per year. The lowest was -26.00% per year. And the median was -26.00% per year.


Oxford Cannabinoid Technologies Holdings EPS (Diluted) Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings EPS (Diluted) Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
EPS (Diluted)
- - - -0.01 -0.01

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Oxford Cannabinoid Technologies Holdings's EPS (Diluted)

For the Biotechnology subindustry, Oxford Cannabinoid Technologies Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Cannabinoid Technologies Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Cannabinoid Technologies Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Oxford Cannabinoid Technologies Holdings's PE Ratio falls into.



Oxford Cannabinoid Technologies Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Oxford Cannabinoid Technologies Holdings's Diluted EPS for the fiscal year that ended in Apr. 2023 is calculated as

Diluted EPS (A: Apr. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.752-0)/960.416
=-0.01

Oxford Cannabinoid Technologies Holdings's Diluted EPS for the quarter that ended in Oct. 2023 is calculated as

Diluted EPS (Q: Oct. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.307-0)/960.416
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Cannabinoid Technologies Holdings  (FRA:0CB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Oxford Cannabinoid Technologies Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines